Delivering powerful cancer testing solutions through our novel NextAmp™ Analysis System – a customizable and dual functionality system, capable of performing both multi-gene expression (PanelChip®) and digital qPCR applications (DigiChip™)
NextAmp™
Analysis System
A dual-functioning system capable of multi-biomarker analysis and digital detection of low quantity genes
Innovation through Collaborations
We collaborate for your success by customizing smarter and more suitable biomarker solution to meet your clinical needs
Increase Precision Therapy Accessibility
Our assays enable more patients to receive suitable drug treatments with the ability to analyze poor quality and low concentration samples
Pinpoint Eligible Patients
PanelChip® offers a cost-effective platform for large scale screening of patient with rare gene rearrangements
Proven Clinical Utility with Expression Biomarkers
Translating discoveries into products, we have launched the first miRNA-based expression assay in the field of reproductive health
Unparalleled Biopharma Solutions
As an enabling technology, NextAmp™ Analysis System offers multiple advantages over Next Generation Sequencing, making it ideal for the development of companion diagnostics during clinical trials and post-marketing commercialization.
Learn more
Collaborator’s Testimonial
“We routinely work with difficult samples such as FFPE, which often cannot meet the quality requirements needed to be run on available genetic testing platforms today. In contrast, NextAmp™ Analysis System provides the flexibility to design amplicons for fragmented RNA, making it possible to develop assays that deal with FFPE samples of various quality.”
Dr. Hua Chien Chen, CEO
ACT Genomics Co.
“QuarkBio’s PanelChip™ multiplexing capability allows us to detect more than 25 respiratory pathogen in one qPCR experiment. The advantage has helped us achieve throughput that we’ve never imagined would be possible!”
